CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.

Clinical Trial Description

The approach builds upon extensive evidence supporting the benefit of CD40L blockade in disrupting key signaling events associated with immune activation. The trial addresses a pressing clinical need, namely prevention of Graft-Versus-Host Disease (GVHD) after hematopoietic cell transplantation (HCT) and promotion of donor-recipient immune tolerance. The safety profile of this anti-CD40L antibody overcomes major prior limitations, and the planned biologic studies will provide significant mechanistic insight. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03605927
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Completed
Phase	Phase 1
Start date	February 15, 2019
Completion date	September 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02066051` - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD	N/A
Terminated	`NCT01940796` - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)	Phase 1
Not yet recruiting	`NCT05544448` - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases	N/A
Completed	`NCT01295710` - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)	Phase 3
Not yet recruiting	`NCT06000982` - Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis	Phase 3
Not yet recruiting	`NCT06075225` - MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib	Phase 2
Active, not recruiting	`NCT03680092` - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation	Phase 2
Not yet recruiting	`NCT06083129` - Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor	Phase 3
Not yet recruiting	`NCT05094765` - Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD	Early Phase 1
Active, not recruiting	`NCT05415410` - Proof-of-concept Trial of Apraglutide in GVHD	Phase 2
Completed	`NCT02441075` - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014	N/A
Completed	`NCT02588339` - Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention	Phase 2
Not yet recruiting	`NCT06334367` - Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT	Phase 2
Completed	`NCT03846479` - Itacitinib for Low Risk GVHD	Phase 2
Completed	`NCT02891603` - A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression	Phase 1/Phase 2
Completed	`NCT02712762` - Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
Completed	`NCT03945591` - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Not yet recruiting	`NCT06411184` - Safety and Efficacy of Treg Cell in the Treatment of GVHD	Phase 1/Phase 2
Terminated	`NCT02338232` - Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation	N/A